A58 Stock Chart & Stats
€331.20
-€0.10(-0.03%)
At close: 4:00 PM EDT
€331.20
-€0.10(-0.03%)
Day’s Range― - ―
52-Week Range€236.30 - €379.10
Previous CloseN/A
Volume4.00
Average Volume (3M)12.00
Market Cap
€72.03B
Enterprise Value€115.45K
Total Cash (Recent Filing)€37.51B
Total Debt (Recent Filing)€31.04B
Price to Earnings (P/E)17.1
Beta0.28
Next Earnings
Oct 21, 2026EPS Estimate
4.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)22.50
Shares Outstanding216,869,300
10 Day Avg. Volume23
30 Day Avg. Volume12
Financial Highlights & Ratios
PEG Ratio-5.70
Price to Book (P/B)1.77
Price to Sales (P/S)0.39
P/FCF Ratio24.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€394.98Price Target Upside19.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering19
EPS Forecast (FY)23.85
Revenue Forecast (FY)€173.17B
Bulls Say, Bears Say
Bulls Say
Scale & Diversified MembershipA 44.9 million member base across commercial, Medicare and Medicaid provides durable revenue scale and diversification. Scale supports negotiating leverage with providers, spreads fixed costs, sustains ASO fee economics, and enables cross-selling of Carelon services to drive long-term stable revenue.
Carelon Scaling And Clinical SavingsCarelon’s programs delivering measurable cost savings (behavioral health ~10%, CareBridge mid-teens) indicate durable competitive advantage: proprietary clinical models and value-based services can be scaled to third-party customers, improving long-term margins and differentiating offerings versus pure payers.
Manageable Leverage And Positive FCFApparent balance-sheet stability (moderate leverage) combined with multibillion-dollar operating and free cash flow supports strategic investments and the ability to fund growth initiatives. This financial flexibility underpins durable execution of Carelon scaling and technology investments despite near-term volatility.
Bears Say
Margin CompressionSustained margin compression reduces earnings resilience: lower net margins reflect elevated medical utilization and cost pressures. Over time this makes profitability more sensitive to utilization and pricing, limiting ability to absorb shocks and requiring consistent execution to restore prior return levels.
Medicaid Headwinds & Market ExitsNegative Medicaid margins and announced market exits signal structural challenges: regulatory reimbursement and program complexity can depress profitability and force retreat from unprofitable markets, shrinking membership and increasing reliance on higher-margin lines to restore enterprise returns.
Cash Conversion VolatilityWeak cash conversion and sharply negative recent FCF growth indicate volatile free cash flows driven by timing and claims dynamics. This reduces financial predictability, constrains capital allocation flexibility for buybacks/dividends, and increases sensitivity to payment timing and regulatory remittances.
Elevance Health News
A58 FAQ
What was Elevance Health’s price range in the past 12 months?
Elevance Health lowest stock price was €236.30 and its highest was €379.10 in the past 12 months.
What is Elevance Health’s market cap?
Elevance Health’s market cap is €72.03B.
When is Elevance Health’s upcoming earnings report date?
Elevance Health’s upcoming earnings report date is Oct 21, 2026 which is in 83 days.
How were Elevance Health’s earnings last quarter?
Elevance Health released its earnings results on Jul 15, 2026. The company reported €6.55 earnings per share for the quarter, beating the consensus estimate of €5.461 by €1.089.
Is Elevance Health overvalued?
According to Wall Street analysts Elevance Health’s price is currently Undervalued.
Does Elevance Health pay dividends?
Elevance Health does not currently pay dividends.
What is Elevance Health’s EPS estimate?
Elevance Health’s EPS estimate is 4.14.
How many shares outstanding does Elevance Health have?
Elevance Health has 216,869,300 shares outstanding.
What happened to Elevance Health’s price movement after its last earnings report?
Elevance Health reported an EPS of €6.55 in its last earnings report, beating expectations of €5.461. Following the earnings report the stock price went down -8.354%.
Which hedge fund is a major shareholder of Elevance Health?
Currently, no hedge funds are holding shares in DE:A58
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elevance Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€394.98 (19.26% Upside)
€394.98 (19.26% Upside)
Blogger Sentiment
Bullish
DE:A58 Sentiment 80%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $541.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.62%
12-Months-Change
Fundamentals
Return on Equity
1.87%
Trailing 12-Months
Asset Growth
3.69%
Trailing 12-Months
Company Description
Elevance Health
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
A58 Company Deck
A58 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly constructive: management reported a quarter that beat expectations, raised 2026 EPS guidance, increased operating cash flow guidance, and highlighted scalable growth drivers (Medicare Advantage improvement, Carelon expansion, and technology-enabled cost management). Notable headwinds remain in Medicaid (projected -1.75% margin), concentrated utilization trends (behavioral health, specialty pharmacy, outpatient surgery, ED), planned market exits, and near-term investments that keep expense ratios elevated. Management emphasized prudence and one-time uses of the Q2 benefit while articulating confidence in returning to at least 12% adjusted EPS growth in 2027 based on diversified levers across the enterprise.View all DE:A58 earnings summariesA58 Stock 12 Month Forecast
Average Price Target
€394.98
▲(19.26% Upside)